Silverstone T
Department of Psychological Medicine, St Bartholomew's Hospital, London, UK.
Int Clin Psychopharmacol. 1993 Jan;7(3-4):133-6. doi: 10.1097/00004850-199300730-00002.
In this paper, three placebo-controlled trials of moclobemide, and four three-way comparison trials of moclobemide, placebo and one of the standard tricyclic antidepressants, imipramine, clomipramine, or amitriptyline, are reviewed. The results of the placebo-controlled trials indicate that about twice as many of the patients receiving moclobemide showed a marked improvement during a four-week treatment period, as compared with patients receiving placebo. Of the three-way trials, two studies indicated that the efficacy of moclobemide was significantly greater than that of placebo and similar to that of other antidepressants (imipramine or amitriptyline). Tolerance of moclobemide was good and better than that of the tricyclic antidepressants. In the other three-way comparison trials, the differences in efficacy between the placebo, moclobemide, and the tricyclic antidepressant were not significant.
本文回顾了三项吗氯贝胺的安慰剂对照试验，以及四项吗氯贝胺、安慰剂与标准三环类抗抑郁药之一（丙咪嗪、氯米帕明或阿米替林）的三方比较试验。安慰剂对照试验的结果表明，在为期四周的治疗期内，接受吗氯贝胺治疗的患者中，病情显著改善的人数约为接受安慰剂治疗患者的两倍。在三方试验中，两项研究表明吗氯贝胺的疗效显著高于安慰剂，且与其他抗抑郁药（丙咪嗪或阿米替林）相似。吗氯贝胺的耐受性良好，优于三环类抗抑郁药。在其他三项三方比较试验中，安慰剂、吗氯贝胺和三环类抗抑郁药之间的疗效差异不显著。
